| Specificity |
The product is specific for Bevacizumab. The antibody is recommended as a capture antibody in a pharmacokinetic (PK) bridging assay with detection antibody GenScript A01962 or A01896, MonoRab™ Anti-Bevacizumab Antibody (46E3), mAb, Rabbit. |
| Host Species |
Mouse |
| Immunogen |
Bevacizumab |
| Conjugate |
Unconjugated |
|
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. |
| Application |
Recommended Usage |
| ELISA |
0.01-0.1 µg/ml |
| Chemiluminescent immunoassay (CLIA) |
0.5-2 µg/ml |
|
| Form |
Lyophilized |
| Storage Buffer |
Lyophilized with PBS, pH 7.2, containing 0.02% sodium azide. |
| Reconstitution |
Reconstitute the lyophilized powder with deionized water (or equivalent) to an final concentration of 0.5 mg/mL. |
| Storage Instructions |
The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles. |
| Purification |
Protein A affinity column |
| Isotype |
Mouse IgG1, κ |
| Clonality |
Monoclonal |
| Clone ID |
11C1 |
| Note |
GenScript can customize this product per customer's request including product size, buffer components, etc. |
Figure 1. ELISA binding of Anti-Bevacizumab Antibody (11C1), mAb, Mouse (GenScript, A02185) with Bevacizumab. While the antibody does not recognize the human IgG (data not shown).
Coating antigen: Bevacizumab, 1 µg/ml.
Anti-Bevacizumab Antibody (11C1), mAb, Mouse (GenScript, A02185) dilution start from 1,000 ng/ml.
Figure 2. Standard curve of Bevacizumab Sandwich CLIA (Chemiluminescent immunoassay).
The Bevacizumab Sandwich CLIA assay is developed by using Anti-Bevacizumab Antibody (11C1), mAb, Mouse (GenScript, A02185) and MonoRab™ Anti-Bevacizumab Antibody (46E3)[Biotin], mAb, Rabbit (GenScript, A01896) as the capture and detection antibodies, respectively.
Capture antibody: Anti-Bevacizumab Antibody (11C1), mAb, Mouse, 1.5 μg/ml
Detection antibody: MonoRab™ Anti-Bevacizumab Antibody (46E3)[Biotin], mAb, Rabbit, 0.5 μg/ml
| Target Background |
Bevacizumab (Avastin) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of a number of types of cancers and a specific eye disease. Bevacizumab binds to a continuous epitope in VEGF, preventing interaction of VEGF with VEGFR on the surface of endothelial cells. It can be used to inhibit solid tumours growth and metastasis by weakening tumour angiogenesis. |
| Synonyms |
Avastin |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
